Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $61.20 | Total: $306.00 |
| 1 | 10 | $51.84 | Total: $518.40 |
| 1 | 25 | $43.92 | Total: $1,098.00 |
| 1 | 50 | $37.44 | Total: $1,872.00 |
| 1 | 100 | $32.40 | Total: $3,240.00 |
Overview
RAGE antagonist peptide acetate is an advanced antagonist of glycation end products (RAGE). RAGE antagonist peptide acetate possesses anti-tumor and anti-inflammatory activities. RAGE antagonist peptide acetate prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4.
Chemical Properties
| Molecular Formula | C59H105N13O19S |
| Molecular Weight | 1332.61 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CC(O)=O.CSCC[C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CC(C)C)=O)CCC(O)=O)=O)CCCCN)=O)CCC(O)=O)=O)NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@@H](NC(C)=O)CCC(O)=O)=O)CC(C)C)=O)CCCCN)=O)=O)CC(C)C)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
Lihong Yao, et al. The receptor for advanced glycation end products is required for ?-catenin stabilization in a chemical-induced asthma model. Br J Pharmacol. 2016 Sep;173[17] 2600-13.